Searching across hundreds of databases
Heightened effector function and prolonged persistence, the key attributes of Th1 and Th17 cells, respectively, are key features of potent anti-tumor T cells. Here, we established ex vivo culture conditions to generate hybrid Th1/17 cells, which persisted long-term in vivo while maintaining their effector function. Using transcriptomics and metabolic profiling approaches, we showed that the enhanced anti-tumor property of Th1/17 cells was dependent on the increased NAD+-dependent activity of the histone deacetylase Sirt1. Pharmacological or genetic inhibition of Sirt1 activity impaired the anti-tumor potential of Th1/17 cells. Importantly, T cells with reduced surface expression of the NADase CD38 exhibited intrinsically higher NAD+, enhanced oxidative phosphorylation, higher glutaminolysis, and altered mitochondrial dynamics that vastly improved tumor control. Lastly, blocking CD38 expression improved tumor control even when using Th0 anti-tumor T cells. Thus, strategies targeting the CD38-NAD+ axis could increase the efficacy of anti-tumor adoptive T cell therapy.
Pubmed ID: 29129787 RIS Download
Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.
Software to manage Seahorse XFe24 Analyzer, which measures OCR and ECAR of live cells in a 24-well plate format. Users can create and modify assay templates and analyze and manage data.
View all literature mentionsThis monoclonal targets IFNγ
View all literature mentionsThis monoclonal targets IL-17A
View all literature mentionsThis polyclonal targets SLC7A11
View all literature mentionsThis unknown targets Rabbit IgG (H+L)
View all literature mentionsThis unknown targets Rabbit IgG (H+L)
View all literature mentionsThis monoclonal targets FoxO1 (C29H4) Rabbit mAb
View all literature mentionsThis monoclonal targets PDHA1
View all literature mentionsThis monoclonal targets Pkm2
View all literature mentionsThis monoclonal targets LDHA
View all literature mentionsThis monoclonal targets GAPDH
View all literature mentionsThis monoclonal targets Hexokinase II
View all literature mentionsThis monoclonal targets Hexokinase I
View all literature mentionsThis polyclonal targets Phospho-FoxO1 (Ser256)
View all literature mentionsThis unknown targets Goat IgG (H+L)
View all literature mentionsThis unknown targets ASCT2
View all literature mentionsThis monoclonal targets TCR V beta 12
View all literature mentionsThis monoclonal targets TCR V beta 14
View all literature mentionsThis monoclonal targets TCR V beta 13
View all literature mentionsThis monoclonal targets CD98
View all literature mentionsThis monoclonal targets CD279
View all literature mentionsThis monoclonal targets CD279
View all literature mentionsThis monoclonal targets CD71
View all literature mentionsThis monoclonal targets CD38
View all literature mentionsThis monoclonal targets CD38
View all literature mentionsThis monoclonal targets CD73
View all literature mentionsThis monoclonal targets CD197
View all literature mentionsThis monoclonal targets CD196
View all literature mentionsThis monoclonal targets CD195
View all literature mentionsThis monoclonal targets IFN-gamma
View all literature mentionsThis monoclonal targets IFN-gamma
View all literature mentionsThis monoclonal targets IL-17A
View all literature mentionsThis monoclonal targets IL-17A
View all literature mentionsThis monoclonal targets CD8a
View all literature mentionsThis monoclonal targets CD8a
View all literature mentionsThis monoclonal targets CD8a
View all literature mentionsThis monoclonal targets CD4
View all literature mentionsThis monoclonal targets CD4
View all literature mentionsThis monoclonal targets CD4
View all literature mentionsThis monoclonal targets EOMES
View all literature mentionsThis monoclonal targets CD90.1 (Thy-1.1)
View all literature mentionsThis monoclonal targets CD90.1 (Thy-1.1)
View all literature mentionsThis monoclonal targets CD39
View all literature mentionsThis monoclonal targets CD45.2
View all literature mentionsThis monoclonal targets CD183 (CXCR3)
View all literature mentionsThis monoclonal targets IRF4
View all literature mentionsThis monoclonal targets ROR gamma (t)
View all literature mentionsThis monoclonal targets T-bet
View all literature mentionsThis monoclonal targets CD4
View all literature mentionsThis monoclonal targets IL-4
View all literature mentionsThis monoclonal targets CD28
View all literature mentionsThis monoclonal targets CD3ε
View all literature mentionsCell line B16-F10 is a Cancer cell line with a species of origin Mus musculus (Mouse)
View all literature mentionsThis monoclonal targets IFNγ
View all literature mentionsThe SciCrunch Infrastructure was developed as a cooperative data platform to be used by diverse communities in making data more FAIR.
scicrunch.org
